TRENDS

• “Huge Seller” Re-Pricing Targeting Hep C Drugs Will Dampen Innovative Market
  December 9, 2015

• Peak Sales Forecast for New Drugs Listed in 2015 Exceeded 840 Billion Yen with Big Contribution from Hep C Treatments
  December 7, 2015

• AG Shares Reach 50-60% in 1 Year; Confidence in Quality Encourages Dominance Even without Market Lead
  November 30, 2015

• Full-Year Forecasts for Domestic Market Down vs Previous Year; Major Makers Struggling Even in Year without NHI Price Revision
  November 11, 2015

• Shift to Specialty - 5: Eisai, Ajinomoto Jump on Specialty Bandwagon to Seek Efficiency in GI Biz
  October 30, 2015

• Drug Makers’ Payments to Medical Institutions Dip for Second Year: Jiho Tally
  September 15, 2015

• Transformation of ARB Market Spurred by AGs, Power Map Changing Fast as Brand-Name Drugs Falter
  September 4, 2015

• Japan Drug Makers See Rising Overseas Sales Ratios in April-June
  August 11, 2015

• IFN-Free Drugs Upending Hepatitis C Market Landscape
  July 17, 2015

• 3 Major Japan Makers Shed 1,300 Jobs amid Redundancy Programs
  June 30, 2015

• “80% Generic” Era Would Further Accelerate Contraction of Market for Long-Listed Drugs
  June 29, 2015

• Top-4 Japanese Drug Makers Report Widely Different Financial Results for FY2014
  May 22, 2015

• Will 5,000 Contract Sales Reps Be Just a Way Station for a Higher Goal Beyond?
  April 24, 2015

• Global Drug Sales Rose 8.8% to US$936.5 Billion in 2014: IMS Health
  April 3, 2015

• Development Tie-Ups with Immune Checkpoint Inhibitors Increase; to Maximize Value through Combination
  March 27, 2015

• Most Global Products on Track to Clear Their FY2014 Sales Forecasts; Abilify Posting Sales of 650 Billion Yen
  March 16, 2015

• Will SGLT-2 Inhibitors Catch On? Breakout Will Require Accumulation of Data
  February 25, 2015

• Chugai Aims to Surpass 200 Billion Yen in Its Domestic Oncology Sales in 2015
  February 13, 2015

• EFPIA Predicts Growth in Ethical Drug Market to Just 10 Trillion Yen in 2025
  February 6, 2015

• Edoxaban Approved in US with Restriction on Use; Impact on Daiichi Sankyo’s Midterm Business Plan Remains Unclear
  January 30, 2015

ページ